Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MLYCD | O95822 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13158468 | 0.97 | NPC1 (0.50) | MAPK14L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13158464 | 0.93 | PTGS2 (0.46) | MAPK14NPC1RAB9ASMN1; SMN2REV1 | |
| SCHEMBL3105762 | 0.89 | PTGS2 (0.46) | RAB9APTGS2CA2CA1TP53 | |
| SCHEMBL13158428 | 0.88 | PTGS2 (0.46) | MAPK14RAB9APTGS2CA2CA1 | |
| SCHEMBL3110664 | 0.88 | MAPK14 (0.47) | MAPK14L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13158458 | 0.87 | PTGS2 (0.52) | NPC1RAB9ASMN1; SMN2PTGS2CA2 | |
| SCHEMBL13158440 | 0.86 | MAPK14 (0.52) | MAPK14NPC1RAB9ASMN1; SMN2PTGS2 | |
| SCHEMBL13158474 | 0.86 | RAB9A (0.49) | NPC1RAB9ASMN1; SMN2MLYCDREV1 | |
| SCHEMBL3112608 | 0.84 | NPC1 (0.48) | MAPK14L3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13158457 | 0.84 | MAPK14 (0.48) | MAPK14RAB9AMLYCDPTGS2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105253-A1 | Triazole Derivative and Use Thereof | F2R, HRH4, F2RL3 | MAPK14 1769/4885L3MBTL1 1781/4885NPC1 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.